Assenagon Asset Management S.A. Sells 415,812 Shares of FibroGen, Inc. (NASDAQ:FGEN)

Assenagon Asset Management S.A. reduced its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 54.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 351,851 shares of the biopharmaceutical company’s stock after selling 415,812 shares during the period. Assenagon Asset Management S.A. owned approximately 0.35% of FibroGen worth $186,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of FGEN. JPMorgan Chase & Co. lifted its stake in shares of FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares in the last quarter. AQR Capital Management LLC grew its position in FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after acquiring an additional 769,586 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares during the last quarter. FMR LLC boosted its holdings in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares during the period. Institutional investors own 72.71% of the company’s stock.

FibroGen Price Performance

Shares of FibroGen stock opened at $0.51 on Friday. The stock has a market cap of $51.29 million, a PE ratio of -0.41 and a beta of 0.75. FibroGen, Inc. has a 1 year low of $0.18 and a 1 year high of $2.93. The firm has a fifty day moving average price of $0.47 and a 200 day moving average price of $0.49.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period last year, the firm earned ($0.52) earnings per share. As a group, equities analysts expect that FibroGen, Inc. will post -0.8 EPS for the current year.

Wall Street Analysts Forecast Growth

FGEN has been the topic of several analyst reports. HC Wainwright raised FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. Finally, StockNews.com began coverage on FibroGen in a research report on Wednesday, January 1st. They set a “hold” rating for the company.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.